Amplexd Therapeutics is a clinical stage biotech firm managed by patient scientists situated in Gaithersburg, MD. The company has secured $2 million in investment.
Investor
- Afamily office with a concentration on life sciences in Asia.
Use of funds
The cash will be used by the firm to complete the development and IND applications in preparation for the anticipated start of first-in-human clinical trials later this year.
About Amplexd Therapeutics
Cervical precancer, or cervical intraepithelial neoplasia, is being treated with two inexpensive, non-invasive medicines being developed by Amplexd Therapeutics, led by CEO Alia Rahman. Both treatments are intended to specifically target neoplastic cells: the first is an intravaginal suppository for low-grade CIN, while the second is a photodynamic therapy (PDT) device for high-grade CIN. By avoiding intrusive operations, these therapies aim to both update the paradigm for women in wealthy countries and give those in low- and middle-income areas access to potentially life-saving care.
